Lupin

New Delhi, May 31 (UNI) Lupin Ltd today said it will not pursue the MoU with Symbiotec Pharmalab Ltd (SPL) as announced earlier.

The company had earlier signed an MoU with SPL, an Indian company focussed on steroids, for a joint venture by making an equity investment in Symbiotec for a majority stake.

Based on subsequent discussions, both the parties have now mutually agreed not to pursue the said MoU. Both companies will however, continue discussions for possible areas of cooperation in the future.

UNI